Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana...

Area of Science:

• Ophthalmology
• Retinal Surgery
• Ocular Inflammation

Background:

• Pars plana vitrectomy (PPV) is a common surgical procedure.
• Postoperative inflammation and pain are significant concerns following PPV.
• Standard treatment involves topical steroid therapy, which can have limitations.

Purpose of the Study:

• To assess the safety and efficacy of a dexamethasone sustained-release intracanalicular insert (DII) for inflammation and pain control after PPV.
• To compare DII performance against standard topical steroid therapy.
• To evaluate DII's impact on key postoperative ophthalmic parameters.

Main Methods:

• Retrospective, case-matched study comparing patients receiving DII versus topical steroids post-PPV.
• Primary outcome: complete anterior chamber cell clearance (ACCC) at postoperative day 7.
• Secondary outcomes: intraocular pressure (IOP), central foveal thickness (CFT) via OCT, and cystoid macular edema (CME).

Main Results:

• DII group showed a significantly higher rate of complete ACCC (65% vs. 35%, p=0.01).
• No significant difference in IOP spikes or CME development between groups.
• Mean OCT CFT decreased in both groups, indicating reduced macular edema.

Conclusions:

• The dexamethasone intracanalicular insert (DII) demonstrated excellent safety and efficacy.
• DII provides effective control of postoperative inflammation following pars plana vitrectomy.
• DII represents a promising alternative to standard topical steroid regimens.